Your browser doesn't support javascript.
loading
Risk factors for radiation-induced lung injury in patients with advanced non-small cell lung cancer: implication for treatment strategies.
Sha, Sha; Dong, Jigang; Wang, Maoyu; Chen, Ziyu; Gao, Peng.
Afiliación
  • Sha S; Department of Radiotherapy, Jiaozhou Central Hospital, No. 29 Xuzhou Road, Jiaozhou City, Qingdao, 266300, China. shasha_qjch@yeah.net.
  • Dong J; Department of Radiotherapy, Jiaozhou Central Hospital, No. 29 Xuzhou Road, Jiaozhou City, Qingdao, 266300, China.
  • Wang M; Department of Radiotherapy, Jiaozhou Central Hospital, No. 29 Xuzhou Road, Jiaozhou City, Qingdao, 266300, China.
  • Chen Z; Department of Radiotherapy, Jiaozhou Central Hospital, No. 29 Xuzhou Road, Jiaozhou City, Qingdao, 266300, China.
  • Gao P; Department of Radiotherapy, Jiaozhou Central Hospital, No. 29 Xuzhou Road, Jiaozhou City, Qingdao, 266300, China.
World J Surg Oncol ; 19(1): 214, 2021 Jul 16.
Article en En | MEDLINE | ID: mdl-34271911
ABSTRACT

BACKGROUND:

The radiation-induced lung injury (RILI) in patients with advanced non-small cell lung cancer (NSCLS) is very common in clinical settings; we aimed to evaluate the risk factors of RILI in NSCLS patients, to provide insights into the treatment of NSCLS.

METHODS:

NSCLC patients undergoing three-dimensional conformal radiotherapy (3D-CRT) in our hospital from June 1, 2018, to June 30, 2020, were included. The characteristics and treatments of RILI and non-RILI patients were analyzed. Logistic regression analyses were conducted to assess the risk factors of RILI in patients with NSCLC.

RESULTS:

A total of 126 NSCLC patients were included; the incidence of RILI in NSCLC patients was 35.71%. There were significant differences in diabetes, smoke, chronic obstructive pulmonary disease (COPD), concurrent chemotherapy, radiotherapy dose, and planning target volume (PTV) between the RILI group and the non-RILI group (all P < 0.05). Logistic regression analyses indicated that diabetes (OR 3.076, 95%CI 1.442~5.304), smoke (OR 2.745, 95%CI 1.288~4.613), COPD (OR 3.949, 95%CI 1.067~5.733), concurrent chemotherapy (OR 2.072, 95%CI 1.121~3.498), radiotherapy dose ≥ 60 Gy (OR 3.841, 95%CI 1.932~5.362), and PTV ≥ 396 (OR 1.247, 95%CI 1.107~1.746) were the independent risk factors of RILI in patients with NSCLC (all P < 0.05).

CONCLUSIONS:

RILI is commonly seen in NSCLS patients; early targeted measures are warranted for patients with those risk factors; future studies with larger sample sizes and different areas are needed to further elucidate the influencing factors of RILI in the treatment of NSCLS.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Radioterapia Conformacional / Lesión Pulmonar / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: World J Surg Oncol Año: 2021 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Radioterapia Conformacional / Lesión Pulmonar / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: World J Surg Oncol Año: 2021 Tipo del documento: Article País de afiliación: China